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Objective: The objective of this thesis is to investigate the effects of maternal thyroid 
dysfunction on maternal pregnancy outcomes.  
Setting and Participants: The NICHD Consecutive Pregnancy data set contains 
information on a total of 114,679 pregnancies from 51,086 women who delivered ≥ 20 
weeks of gestation. The data come from 20 different hospitals throughout the state of 
Utah and were collected between the years of 2002 to 2010. 
Main Outcomes: Main outcomes of interest included: breech presentation, 
chorioamnionitis, gestational diabetes, gestational hypertension, hemorrhage, 
inductions, placental abruption, placental previa, preterm birth, premature rupture of 
membranes (PROM), preeclampsia, and superimposed preeclampsia. 
Methods: Results are presented as RRs with 95% CIs. RRs are obtained from modified 
Poisson regression models. Analyses are to singleton pregnancies. All results are 
adjusted for insurance, parity, race/ethnicity, age, smoking, and other chronic diseases.  
Results: We found that hypothyroidism is significantly associated with gestational 
diabetes [RR: 1.28, 95% CI: 1.00-1.63], gestational hypertension [RR: 1.32, 95% CI: 1.07-
 
iv 
1.63], inductions [RR: 0.98, 95%CI: 0.96-0.99] and preterm birth [RR: 1.23, 95% CI: 1.08-
1.41] after adjusting for confounders. Hyperthyroidism was found to be significantly 
associated with gestational diabetes [RR: 2.47, 95% CI: 1.28-4.76], preterm birth [RR: 
2.31, 95% CI: 1.61-3.32], and preeclampsia [RR: 2.65, 95% CI: 1.44-4.87] after adjusting 
for confounders. Unspecified thyroid disorders were significantly associated with 
gestational hypertension [RR: 1.24, 95% CI: 1.01-1.53], placental abruption [RR: 1.29, 
95% CI: 1.01-1.64], and preterm birth [RR: 1.20, 95% CI: 1.05-1.37] after adjusting for 
confounders. Adjusted results for other thyroid disorders were not significant.  
Conclusions: The results of this study suggest that the presence of a thyroid disorder 
increases the risk of adverse outcomes during pregnancy. This supports previous 
findings but more research involving large racially diverse cohorts with available data on 
treatment is needed to further understand the complex association between thyroid 
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Thyroid disorders are the second most common endocrine disorders affecting 
women during their reproductive years and can impact up to 4% of all pregnancies1. Of 
all thyroid disorders, hypothyroidism is the most prevalent, impacting approximately 2-
3% of all pregnancies 2. Hyperthyroidism is far less prevalent, impacting approximately 
0.2% of all pregnancies2. Thyroid disorders during pregnancy have been associated with 
a various number of adverse outcomes among both mothers and newborns. Specifically, 
multiple studies have found hypothyroidism to be associated with anemia, postpartum 
hemorrhage, placental abruption, gestational diabetes, cardiac dysfunction, preterm 
birth, miscarriage and fetal death 3-6, 9-14. Additionally, studies have found 
hyperthyroidism to be associated with an increased risk for hypertension during 
pregnancy, maternal heart failure, preterm birth, miscarriage, and stillbirth7-9, 11-12.  
1.2 HYPOTHYROIDISM 
 Hypothyroidism, also referred to as underactive thyroid, is a condition in which 
the thyroid gland does not produce a sufficient amount of thyroid hormone15. As a 
result, the body’s metabolism slows down which can cause symptoms including but not 
limited to: fatigue, lethargy, constipation, weight gain, joint or muscle pain, irregular 
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menstrual periods, pale or dry skin, depression, weakness, and increased sensitivity to 
cold temperatures15,16. Hypothyroidism can be caused by numerous disorders and by 
conditions, some of the most common being: viral infections, autoimmune disorders, 
pregnancy, medications, radiation treatments, pituitary tumors, and congenital birth 
defects16. A diagnosis of hypothyroidism results from the presence of symptoms, and 
high levels of thyroid-stimulating hormone and low levels of thyroxine as determined by 
laboratory tests15. Hypothyroidism is generally treated with hormone replacement 
therapy which has shown to be effective in reducing the effects of the disease15. 
However, if left untreated, the symptoms may become more severe and can lead to 
difficulty in breathing, mental health problems, goiter, heart complications, and life-
threatening coma16.  
1.3 HYPERTHYROIDISM 
Hyperthyroidism is a condition in which the thyroid produces too much of the 
thyroid hormone17. This results in an overactive thyroid and can produce symptoms 
such as weight loss, chest pain, palpitations, diarrhea, nervousness, difficulty 
concentrating, fatigue, and increased appetite17, 18. Hyperthyroidism can be caused from 
various conditions and diseases including but not limited to: Graves’ disease, consuming 
too much iodine, noncancerous growths of the thyroid or pituitary gland, and 
inflammation of the thyroid due to viral infections, medications, or pregnancy17, 18. 
Diagnosis involves the presence of symptoms in addition to blood tests indicating high 
levels of thyroxine and low levels of thyroid stimulating hormone18. Additionally, radio 
iodine uptake tests and thyroid scans may be used to confirm the diagnosis18.  The main 
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treatment options for hyperthyroidism involve the use of antithyroid drugs, the removal 
of thyroid gland tissue, and radioiodine therapy17, 18. It is important to note that 
treatment of hyperthyroidism has the potential to result in hypothyroidism, which 
ultimately will lead to the requirement of lifetime hormone replacement therapy18. 
1.4 PURPOSE AND SPECIFIC AIMS  
 The purpose of this paper will be to further examine the association between 
thyroid disorders and adverse pregnancy outcomes. Based on previous findings, we 
hypothesize that thyroid disorders are associated with increased risks of adverse 
maternal outcomes. This study’s aims and objectives is to evaluate the association of 
thyroid disorders on adverse pregnancy outcomes, specifically, hypothyroidism, 
hyperthyroidism, other thyroid disorders, and unspecified thyroid disorders. 
1.5 ORGANIZATION OF THESIS 
 Chapter I has provided sufficient background information on both the exposure 
and outcomes of interest, in addition to outlining the main aims and objectives of this 
thesis. Chapter II will consist of a literature review covering previous findings on the 
influence of thyroid disorders on pregnancy outcomes and demonstrate how this thesis 
will address some questions. Chapter III will explain in detail the methods of research 
and statistical techniques used to analyze the data. The results of the analyses will be 








2.1 THYROID DISORDERS AND PREGNANCY 
Thyroid disorders are fairly common during pregnancy and have been shown to 
impact up to 4% of all pregnancies1. Pregnancy results in a number of physiological and 
hormonal changes that may alter thyroid function2. In order to maintain normal energy 
and lipid metabolism, normal thyroid function is needed9. It is postulated that 
inadequate regulation of thyroid hormones may result in adverse outcomes during 
pregnancy 2, 3, 9. Additionally, weight gain or lipid disturbances that are often associated 
with hypothyroidism may increase the risk of adverse pregnancy outcomes9, 3. 
One of the largest studies that investigated the relationship between thyroid 
disorders and maternal outcomes is by Männistö et al9. The main objective of this study 
was to investigate pregnancy complications (hypertensive diseases, diabetes, preterm 
birth, cesarean sections, inductions, and intensive care unit admissions) associated with 
both common and uncommon forms of thyroid disease9. Data from the Consortium on 
Safe Labor (2002–2008), a retrospective US cohort, were analyzed using multivariable 
logistic regression fitted by generalized estimating equations in order to obtain odds 
ratios (ORs) with 99% confidence intervals (99% CI)9.  
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The study found primary hypothyroidism to be significantly associated with 
increased odds of preeclampsia [OR: 1.47; 99% CI: 1.20, 1.81], superimposed 
preeclampsia [OR: 2.25; 99% CI: 1.53, 3.29], gestational diabetes [OR: 1.57; 99% CI:1.33, 
1.86], preterm birth [OR: 1.34 ; 99% CI: 1.17,1.53], induction [OR:1.15; 99% CI: 
1.04,1.28], cesarean section [pre-labor OR: 1.31; 99% CI: 1.11,1.54; after spontaneous 
labor OR:1.38; 99% CI:1.14,1.66], and ICU admissions [OR: 2.08; 99% CI: 1.04, 4.15]9. 
Iatrogenic hypothyroidism was significantly associated with the increased odds of 
placental abruption [OR: 2.89; 99% CI: 1.14, 7.36], breech presentation [OR: 2.09; 99% 
CI: 1.07, 4.07], and cesarean section after spontaneous labor [OR: 2.05; 99% CI: 1.01, 
4.16]9. Hyperthyroidism was significantly associated with the increased odds of 
placental abruption [OR: 2.89; 99% CI: 1.14, 7.36), breech presentation [OR: 2.09; 99% 
CI: 1.07, 4.07], and cesarean section after spontaneous labor [OR: 2.05; 99% CI: 1.01, 
4.16]9. These results indicate that thyroid diseases are associated with significant 
increases in morbidity during pregnancy and are consistent with previous research 3-14. 
Additionally, one particular paper by Becks et al, stresses that both maternal and 
neonatal outcomes in pregnancy are adversely affected by multiple thyroid disorders, 
especially if they go undiagnosed or untreated10. Medici et al also found that even small 
subclinical variations in thyroid function have been associated with detrimental 
pregnancy outcomes, including low birth weight and pregnancy loss14. These studies 
support the findings by Männistö and support the association between thyroid disorders 
and adverse pregnancy outcomes.  A summary of the findings of epidemiologic studies 
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on the association between thyroid disorders and pregnancy can be found in table 2.1 at 
the end of the chapter. 
2.2 HYPOTHYROIDISM DURING PREGNANCY 
Studies have shown hypothyroidism to be significantly associated with adverse 
pregnancy complications3-6, 9-14,19-20. Maraka et al conducted a systematic review and 
meta-analysis of results from randomized trials and cohort studies to further investigate 
the relationship between hypothyroidism and pregnancy outcomes19. They focused on 
the following main outcomes: pregnancy loss, preterm labor, preterm delivery, 
gestational hypertension, preeclampsia, eclampsia, gestational diabetes, placental 
complications, premature rupture of membranes, cesarean delivery, intrauterine 
growth restriction, low birth weight (≤2500 g), low Apgar score (≤7 at 5 min), small for 
gestational age, and neonatal death19. The pooled estimates showed that pregnancy 
loss [RR 2.01; 95% CI 1.66–2.44], placental abruption [RR 2.14; 95% CI 1.23–3.70], 
premature rupture of membranes (PROM) [RR 1.43; 95% CI 1.04–1.95], and neonatal 
death [RR 2.58; 95% CI 1.41–4.73] were significantly increased among women with 
hypothyroidism as compared to women without a thyroid condition19. A different meta-
analysis conducted by Sheehan investigated the relationship between maternal thyroid 
disease and preterm birth and found similar results in regards to adverse outcomes and 
thyroid disorders20. Specifically, the results of the study indicated that overt 
hypothyroidism was positively associated with preterm birth with an OR of 1.19 and a 
95% CI: 1.12-1.2620.  
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 Other studies have also found hypothyroidism to be associated with an 
increased risk of adverse pregnancy complications3-6. Casey et al investigated this 
relationship between hypothyroidism and pregnancy outcomes such as hypertension, 
preterm birth, low birth weight, placental abruption, and fetal death4. Most notably the 
results of the study found pregnancies in women with hypothyroidism to be 3 times 
more likely to be complicated by placental abruption [RR: 3.0, 95% CI: 1.1-8.2] and 
almost 2 times as likely to experience preterm birth [RR: 1.8, 95% CI: 1.1-2.9]4. Allan et 
al examined the relationship between pregnancy complications and thyroid deficiency5. 
Specifically, the study looked at vaginal bleeding, premature delivery, low birthweight, 
abruptio placentae, pregnancy induced hypertension, need for cesarean section, low 
Apgar scores, and fetal and neonatal death5. The results indicated that fetal death is 
significantly associated with thyroid-stimulating hormone (TSH) deficiency and other 
major adverse obstetrical outcomes 5.  
Davis et al also investigated the relationship between hypothyroidism and 
pregnancy outcomes3 and showed that hypothyroidism was associated with a slight 
insignificant increase in preeclampsia, placental abruption, anemia, postpartum 
hemorrhage, cardiac dysfunction, and adverse perinatal outcomes3. The study also 
emphasized the importance of proper treatment of thyroid disorders in reducing 
adverse pregnancy outcomes in women with thyroid disorders3. However, the results 





2.3 HYPERTHYROIDISM DURING PREGNANCY 
 Hyperthyroidism has also been found to be associated with adverse pregnancy 
outcomes. However, there has been far less research on hyperthyroidism compared to 
hypothyroidism given its lower prevalence. Previous research indicates that 
hyperthyroidism is associated with increased risks of adverse outcomes such as preterm 
birth, low birth weight, placental complications, cardiomyopathy, retinopathy of 
prematurity, and neonatal thyroid diseases7-9, 11-12, 19-20. 
 Millar et al, examined if controlling hyperthyroidism during pregnancy reduces 
the risk of low birth weight and preeclampsia7. The results of the study showed that lack 
of control of hyperthyroidism significantly increases the risk of low birth weight infants 
[OR: 9.24, 95% CI 5.47-15.6] and severe preeclampsia [OR: 4.74, 95% CI: 1.14-19.7]7. 
Davis et al also investigated the adverse effects of hyperthyroidism and its control on 
pregnancy outcomes8. The study compared pregnancy outcomes for women who were 
both treated and untreated for hyperthyroidism during pregnancy8. The results of the 
study showed that hyperthyroidism is associated with an increased risk of stillbirth, 
preterm birth, and maternal heart failure in both women who had been treated for 
hyperthyroidism and in those who had not received treatment8.  
2.4 GAPS IN THE LITERATURE 
Previous research has indicated that thyroid disorders are associated with 
obstetrical, labor, and delivery complications3-6, 9-14,19-22. However, not all previous 
studies have found this to be consistently true23-26. While some studies did find 
associations between thyroid disorders and pregnancy outcomes, unlike other findings3-
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14, the associations were not significant 23-26. These inconsistencies in the literature may 
be the result of differences in populations, definition of thyroid dysfunction, and 
patient’s baseline characteristics27.   
Additionally, there have been a limited number of large contemporary studies 
that have investigated the influence of thyroid disorders on adverse pregnancy 
outcomes. This is especially true for hyperthyroidism which has been found to affect 
0.2% of all pregnancies2.  Given the low rate of hyperthyroidism, the association 
between hyperthyroidism and pregnancy outcomes has not been explored in as great 
detail as hypothyroidism and therefore more research is needed to further understand 
this association.2 
2.5 MOVING FORWARD 
This paper will investigate the relationship between thyroid disorders and 
maternal outcomes. Based on previous findings, we hypothesize that the presence of 
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Study Sample Exclusion 
Criteria 





The study was limited to 
women with singleton 
pregnancies who had 
undergone prenatal 
screening for neural tube 
defects and Down’s 
syndrome. 
Birth weight, gestational age, 
abruptio placentae, pregnancy 
induced hypertension, cesarean 
delivery, Apgar score at 5 minutes, 
fetal death, neonatal death 
 
 
“The major adverse obstetrical 
outcome associated with raised TSH in 
the general population is an increased rate 





The analysis was limited 
to singleton pregnancies 
without history of thyroid 
disease. Additionally, 
pregnancies complicated 
by preeclampsia were 
excluded. 
Preterm delivery “In pregnancies resulting in spontaneous early preterm 
delivery, there is no evidence of increased prevalence of 
antithyroid antibody positivity or maternal thyroid 





Women who had 
abnormally elevated 
serum TSH levels 
accompanied by 
abnormally low free 
thyroxine levels, were 
determined to have overt 
hypothyroidism and 
therefore excluded from 
the analysis. 
Pregnancy Outcomes: hypertension, 
placental abruption, weeks gestation 
at delivery, cesarean delivery  
Infant Outcomes: birth weight, 
admission to intensive care, Apgar 
score at 5 minutes, umbilical artery 
blood pH, respiratory distress 
syndrome, necrotizing enterocolitis, 
intraventricular hemorrhage, major 
malformations, fetal death, neonatal 
deaths  
“Pregnancies in women with subclinical hypothyroidism 
were 3 times more likely to be complicated by placental 
abruption (relative risk 3.0, 95% confidence interval 1.1–
8.2). Preterm birth, defined as delivery at or before 34 
weeks of gestation, was almost 2-fold higher in women 
with subclinical hypothyroidism (relative risk, 1.8, 95% 
confidence interval 1.1–2.9).”4 (abstract) 
  





(n=8012) Analysis excluded women 
with the following 
conditions: overt thyroid 
disorder, previous or 
present use of thyroxin or 
anti-thyroid drugs, other 
autoimmune disease, 
congenital heart disease, 
and elevated serum 
transaminase or 
creatinine level. 
Gestational hypertension (GH), 
gestational diabetes mellitus, 
placenta previa, placental abruption, 
prelabor rupture of membranes 
(PROM), premature delivery, 
intrauterine growth restriction 
(IUGR), fetal distress, low birth 
weight (LBW; live birth weight <= 
2500 g), stillbirth, and malformation 
“Compared with euthyroid status, SCH was associated 
with higher rates of GH (1.819% vs. 3.504%, P = 0.020; 
chi(2) = 7.345; odds ratio (OR), 2.243; 95% confidence 
interval (CI), 1.251-4.024), PROM (4.973% vs. 8.625%, P = 
0.002; chi(2) = 72.102; adjusted OR, 6.014; 95% CI, 3.975-
9.099), IUGR (1.008% vs. 2.965%, <0.001; chi(2) = 13.272; 
adjusted OR, 3.336; 95% CI, 1.745-6.377), and LBW 
(1.885% vs. 4.582%, P<0.001; chi(2) = 13.558; adjusted 






The analysis was limited 
to singleton intrauterine 
pregnancy without 
evidence of anencephaly 
or cystic hygroma.  
Miscarriage, gestational 
hypertension, preeclampsia, 
gestational diabetes , Placenta previa, 
placental abruption , preterm labor, 
preterm premature rupture of 
membranes, preterm delivery, low 
birth weight, macrosomia, and 
perinatal mortality  
“Subclinical hypothyroidism was not associated with 
adverse outcomes. In the first trimester, 
hypothyroxinemia was associated with preterm labor 
(adjusted odds ratio [aOR] 1.62; 95% confidence interval 
[CI] 1.00-2.62) and macrosomia (aOR 1.97; 95% Cl 1.37-
2.83). In the second trimester, it was associated with 
gestational diabetes (aOR 1.7; 95% Cl 1.02-2.84). Fifteen 
percent (1,585 of 10,990) in the first and 14% (1,491 of 
10,990) in the second trimester had antithyroid 
antibodies. When both antibodies were positive in either 
trimester, there was an increased risk for preterm 
premature rupture of membranes (P=.002 and P <.001, 
respectively)…Maternal thyroid hypofunction is not 






The analysis was limited 
to singleton pregnancies 
that were complicated by 
thyrotoxicosis.  
Thyroxine, pulse rate, preeclampsia, 
gestational age, pregnancy weight 
gain, heart failure, thyrotoxicosis, 
hypothyroidism, goiter, birth weight, 
abortions, still births 
“uncontrolled thyrotoxicosis caused significant maternal 
and perinatal morbidity, aggressive medical therapy 
seems appropriate, especially when pregnancy is 
advanced.”8 (abstract) 
  







The study was limited to 
women with singleton 
pregnancies. 
Gestational diabetes, gestational 
hypertension/preeclampsia, cesarean 
section, preterm delivery, low birth 
weight, and small-for-gestational-age 
neonates. 
“The combination of high TSH and thyroid autoimmunity 
in early pregnancy was associated with a 4-fold increased 
risk for gestational diabetes [relative risk (RR) 4.3, 95% 
confidence interval (CI) 2.1-8.9)] and a 3-fold increased 
risk for low birth weight neonates (RR 3.1,95% CI 1.2-8.0) 
after adjustment for several confounders. Women 
positive for thyroid antibodies without elevated TSH 
levels in early pregnancy were at high risk for 
spontaneous preterm delivery (RR 1.7, 95% CI 1.1-2.8), 
whereas the combined effect of high TSH and positive 
thyroid antibodies did not show an association with 





Analysis was limited to 
singleton pregnancies. 
Participants who did not 
provide blood samples or 
provided serum samples 
after the 18th week of 
gestation were excluded. 
Additionally, women with 
incomplete information 
on outcome variables 
were also excluded. 
Gestational diabetes, gestational 
hypertension/preeclampsia, cesarean 
section, preterm delivery, low birth 
weight, and small-for-gestational-age 
neonates. 
“The combination of high TSH and thyroid autoimmunity 
in early pregnancy was associated with a 4-fold increased 
risk for gestational diabetes [relative risk (RR) 4.3, 95% 
confidence interval (CI) 2.1-8.9)] and a 3-fold increased 
risk for low birth weight neonates (RR 3.1,95% CI 1.2-8.0) 
after adjustment for several confounders. Women 
positive for thyroid antibodies without elevated TSH 
levels in early pregnancy were at high risk for 
spontaneous preterm delivery (RR 1.7, 95% CI 1.1-2.8), 
whereas the combined effect of high TSH and positive 
thyroid antibodies did not show an association with 
preterm birth.” 25 (abstract) 
León 
(2015)22 
(n= 2170) Analysis was limited to 
women with singleton 
pregnancies.  
Birthweight, small and large for 
gestational age (SGA/LGA), and 
preterm delivery 
“An inverse association of fT4 and TSH with birthweight 
was found, the former remaining when restricted to 
euthyroid women. High fT4 levels were also associated 
with an increased risk of SGA [odds ratio, 95% confidence 
interval (CI) 1.28 (95% CI 1.08, 1.51)]. Mean birthweight 
was higher in the hypothyroxinaemic group (β = 109, 
P < 0.01). Iodine intake and UIC were not associated with 
birth outcomes… High maternal fT4 levels during the first 
half of pregnancy were related to lower birthweight and 
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increased risk of SGA newborns, suggesting that maternal 
thyroid function may affect fetal growth, even within the 





The analysis was limited 
to singleton pregnancies. 
Women diagnosed with 
chronic hypertension 
were excluded from the 
analyses of gestational 
hypertension and 
preeclampsia. Additionally 
women who were 
diagnosed with 
preexisting diabetes were 
excluded from the 
analyses of gestational 
diabetes. 
Pre-labor cesarean section, induction, 
spontaneous labor, route of delivery, 
preterm birth (<37 gestational 
weeks), late preterm birth (delivery 
between 34 and <37 weeks), early 
preterm birth (<34 weeks), 
gestational diabetes, gestational 
hypertension, preeclampsia, 
superimposed preeclampsia, 
placental abruption, threatened 
preterm birth, placenta previa, 
hemorrhage in late pregnancy or 
postpartum, chorioamnionitis, 
premature rupture of membranes 
(PROM), preterm premature rupture 
of membranes (PPROM) (PROM <37 
weeks), breech presentation, 
maternal intensive care unit (ICU) 
admission, and maternal death. 
“Primary hypothyroidism was associated with increased 
odds of preeclampsia (OR = 1.47, 99% CI = 1.20-1.81), 
superimposed preeclampsia (OR = 2.25, 99% CI = 1.53-
3.29), gestational diabetes (OR = 1.57, 99% CI = 1.33-
1.86), preterm birth (OR = 1.34, 99% CI = 1.17-1.53), 
induction (OR = 1.15, 99% CI = 1.04-1.28), cesarean 
section (prelabor, OR = 1.31, 99% CI = 1.11-1.54; after 
spontaneous labor OR = 1.38, 99% CI = 1.14-1.66), and 
ICU admission (OR = 2.08, 99% CI = 1.04-4.15). Iatrogenic 
hypothyroidism was associated with increased odds of 
placental abruption (OR = 2.89, 99% CI = 1.14-7.36), 
breech presentation (OR = 2.09, 99% CI = 1.07-4.07), and 
cesarean section after spontaneous labor (OR = 2.05, 99% 
CI = 1.01-4.16). Hyperthyroidism was associated with 
increased odds of preeclampsia (OR = 1.78, 99% CI = 1.08-
2.94), superimposed preeclampsia (OR = 3.64, 99% CI = 
1.82-7.29), preterm birth (OR = 1.81, 99% CI = 1.32-2.49), 
induction (OR = 1.40, 99% CI = 1.06-1.86), and ICU 





The analysis was limited 
to singleton pregnancies.  
Respiratory distress syndrome, 
intracerebral hemorrhage, seizures, 
oliguria, cardiomyopathy, peri- or 
intraventricular hemorrhage, 
necrotizing enterocolitis, retinopathy 
of prematurity, sepsis, transient 
tachypnea, anemia, apnea, asphyxia, 
infectious pneumonia, and aspiration 
“Hyperthyroidism and primary hypothyroidism were 
associated with sepsis, respiratory distress syndrome, 
transient tachypnea, and apnea. Iatrogenic 
hypothyroidism was associated with sepsis and neonatal 
anemia. Hyperthyroidism was also associated with rare 
outcomes (prevalence, <1%) including cardiomyopathy, 
retinopathy of prematurity, and neonatal thyroid 




(n = 9247) 
The analysis was limited 
to singleton pregnancies.  
Perinatal mortality, preterm delivery, 
absolute and gestational age-
“First-trimester antibody positivity is a risk factor for 
perinatal death but not thyroid hormone status as such. 
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adjusted birth weight, and absolute 
and relative placental weight. 
Thyroid dysfunction early in pregnancy seems to affect 




(n = 5805) 
Analysis was limited to 
mothers with singleton 
pregnancies. Women with 
previous diagnoses 
diabetes, hypertension, or 
thyroid disease of before 
pregnancy were excluded 
from analyses of the 
disease in question. 
preeclampsia and gestational 
diabetes 
“Thyroid dysfunction and antibodies were not associated 
with pregnancy complications. Overt hypothyroidism was 
associated with subsequent maternal thyroid disease 
[hazard ratio (HR) (95% confidence interval), 17.7 (7.8-
40.6)] and diabetes [6.0 (2.2-16.4)]. Subclinical 
hypothyroidism [3.3 (1.6-6.9)], TPO-Ab-positivity [4.2 
(2.3-7.4)], and TG-Ab-positivity [3.3 (1.9-6.0)] were also 
associated with later thyroid disease. No association was 
found between thyroid dysfunction/antibodies and 
hypertension or overall mortality.”23 (abstract) 
Maraka 
(2016)19 
(n=3995) Cohort studies as 
randomized control trials 
were examined. Studies 
that lacked the required 
information to determine 
eligibility, and studies that 
reported on a mixed 
population of SCH and OH 
during pregnancy were 
excluded. 
Pregnancy loss, preterm labor, 
preterm delivery, gestational 
hypertension, preeclampsia , 
eclampsia, gestational diabetes, 
placental abruption, placenta previa, 
premature rupture of membranes, 
cesarean delivery, intrauterine 
growth restriction, low birth weight, 
low Apgar score, small for gestational 
age, and neonatal death  
“Compared with euthyroid pregnant women, pregnant 
women with SCH were at higher risk for pregnancy loss 
(relative risk [RR] 2.01 [confidence interval (CI) 1.66-
2.44]), placental abruption (RR 2.14 [CI 1.23-3.70]), 
premature rupture of membranes (RR 1.43 [CI 1.04-




(n=181) Analysis was limited to 
hyperthyroid women with 
singleton pregnancies. 
Preeclampsia, birth weight, preterm 
birth  
“The risk of low birth weight infants was 0.74 (95% 
confidence interval [CI] 0.18-3.08) among controlled 
women, 2.36 (95% CI 1.36-4.12) among women who were 
controlled during pregnancy, and 9.24 (95% CI 5.47-15.6) 
among women who were uncontrolled during pregnancy 
compared to the incidence among non-hyperthyroid 
mothers. The risk of severe preeclampsia was significantly 
higher (odds ratio 4.74, 95% CI 1.14-19.7) among 
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uncontrolled women compared with those who were 





Analysis was limited to 
prospective cohort and 
case-control studies 
where the exposure of 
interest was maternal 
thyroid disease and the 
outcome of interest was 
preterm birth. 
Preterm Birth “The combined OR of preterm delivery for pregnant 
women with overt hypothyroidism compared with the 
reference group was 1.19 (95% CI, 1.12–1.26; P < .00001). 
There was also a significant risk of preterm birth in 
women with hyperthyroidism (OR, 1.24 [95%, CI 1.17–
1.31]; P < .00001). Subclinical hypothyroidism and 
isolated hypothyroxinemia showed no significant increase 
in OR.”20 (abstract) 
Wilson 
(2012)28 
(n=24,883) Women with evidence of 
overt thyroid disease were 
excluded from the 
analyses.  
Hypertension and other 
cardiovascular-related conditions 
during pregnancy 
“The overall incidences of hypertension in pregnancy 
were 6.2%, 8.5%, and 10.9% in the subclinical 
hyperthyroid, euthyroid, and subclinical hypothyroid 
groups, respectively, and were found to be significant 
when unadjusted (P=.016)….Women with subclinical 
hypothyroidism identified during pregnancy have an 
increased risk for severe preeclampsia when compared 






3.1 STUDY POPULATION 
 The NICHD Consecutive Pregnancy data set contains information on a total of 
114,679 pregnancies from 51,086 women who delivered at least twice after 20 weeks of 
gestation. The data comes from 20 different hospitals throughout the state of Utah and 
were collected between the years of 2002 to 2010. Information was extracted by 
hospitals from antepartum and labor and delivery summary electronic medical records. 
Patient information such as demographics, past medical history, reproductive and 
prenatal history, pregnancy, labor and delivery outcomes, postpartum and neonatal 
information were available. Labor and delivery records included data on both the time 
and date of admission, cervical exam on admission, labor and delivery characteristics, 
indications for induction, and indications for cesarean. International Classification of 
Diseases-9 codes from maternal and newborn discharge summaries and patient medical 
records were used to classify the outcomes of each delivery. 
3.2 EXPOSURE OF INTEREST 
The exposure of interest was maternal thyroid disease and was determined 
using electronic medical records and International Classification of Diseases-Ninth 
Edition (ICD-9) codes. Thyroid disease was categorized as no thyroid disease (referent 




thyroid diseases (simple or nontoxic goiter, thyroiditis, and other thyroid disorders 
including benign and malignant thyroid nodules), and unspecified thyroid diseases 
(reported in the medical record but without a discharge ICD-9 diagnostic code). A 
detailed classification of the exposures of interest can be found in table 3.1. 
Additionally, it is important to note that if there were not enough observations available 
within each category, they were combined to aid in the analyses. Specifically, due to a 
limited number of cases of iatrogenic hypothyroidism (n=28), the category was 
combined with primary hypothyroidism. Furthermore, once a mother was diagnosed 
with a thyroid disorder, all subsequent pregnancies were assumed to be affected. 
Table 3.1 Classification of Thyroid Disorder as Classified in the International 
Classification of Diseases, Ninth Edition (ICD-9)  9, 28 

















Other post ablative hypothyroidism 
Iodine hypothyroidism 
Other iatrogenic hypothyroidism 
Congenital hypothyroidism 
Hyperthyroidism 242-242.9 Thyrotoxicosis with or without goiter 




Simple and unspecified goiter 
Nontoxic nodular goiter 
Thyroiditis 






Malignant neoplasm of thyroid gland 
Benign neoplasm of thyroid glands 
3.3 OUTCOMES OF INTEREST 
Outcomes of interest were also classified using electronic medical records and 
International Classification of Diseases-9 (ICD-9) codes. Key outcomes of interest 
included: breech presentation, gestational diabetes, gestational hypertension, 
hemorrhage, inductions, placental abruption, preterm birth, PROM, preeclampsia, and 
superimposed preeclampsia. The ICD-9 codes and definitions of these outcomes are 
listed in Table 3.2.  
Table 3.2 Classification of Outcomes of Interest 9,28 
Outcome ICD-9 Code Source of Data Defined 
Breech Presentation  652.2 ICD9 and EMR Breech presentation without mention 
of version 
Gestational diabetes 648.8 ICD9 and EMR Other current conditions in the 
mothers classifiable elsewhere 
complicating pregnancy, childbirth, or 




642.3 ICD9 and EMR Transient hypertension of pregnancy  
Hemorrhage in Late 
Pregnancy or Post-
Partum 
666-666.3 ICD9 and EMR Postpartum hemorrhage 
Placental Abruption 641.2 ICD9 and EMR Premature separation of placenta  
Preeclampsia 642.4 (mild) 
642.5 
(severe) 





Premature Rupture of 
Membranes  
658.1 ICD9 and EMR Premature rupture of membranes 
Preterm Birth 644.2 ICD9 and EMR <37 Weeks Gestation 
Superimposed 
Preeclampsia 
642.7 ICD9 and EMR Pre-eclampsia or eclampsia 
superimposed on pre-existing 
hypertension 
 
3.4 POTENTIAL CONFOUNDERS 
Covariates included in the model for thyroid disorders and adverse maternal 
outcomes are as follows: maternal age, race/ethnicity, smoking status, hospital of birth, 
parity, insurance status, and other chronic diseases (diabetes, chronic hypertension, 
heart disease, renal disease, depression, seizure disorder, and asthma). Despite the 
knowledge that gestational weight gain is often associated with several of the proposed 
outcomes of interest, it will not be adjusted for in the analyses29. This is due to the fact 
that thyroid diseases are known to cause weight gain or loss, therefore making it a 
collider in the exposure disease pathway9, 29. Thus, adjusting for gestational weight gain 
would potentially introduce bias into the results9,29. Additionally, we are only interested 
in estimating the total effect of the exposure, so no adjustment for gestational weight 
gain will be made. In regards to pre-pregnancy BMI, it will be regarded as a mediator in 
the relationship between thyroid disease and pregnancy outcomes. This is due to the 
fact that thyroid disorders can cause weight loss and gain which influences BMI and in 
turn influences pregnancy outcomes. Therefore, given its position as a mediator in the 




adjustment bias. These relationships are illustrated in the directed acyclic graph (DAG) 
below. 
Figure 3.1 Directed Acyclic Graph46 
 
 3.5 ANALYSIS 
The analysis was limited to singleton pregnancies (n=113,288). Multivariate 
Poisson regression with generalized estimating equations was used as the primary 
method of analysis30. For all analyses, the no thyroid disease category served as the 
comparison group. Results are presented as RRs with their 95% CIs. Estimates of the 
exposure-outcome relationship were obtained, after adjusting for insurance, parity, race 
and ethnicity, age, smoking, and other chronic diseases. For the analyses of gestational 




(n=1,103). For the analyses of gestational diabetes, women with preexisting diabetes 
were excluded (n=1,819). Results from SAS outputs of multivariate Poisson regression 
with generalized estimating equations can be found in Appendix A. Additionally, a 
sensitivity analysis restricting the sample to women with their first delivery only was 
conducted using Poisson regression with generalized estimating equations (n= 50628). 
Statistical significance was set at the 5% level. Statistical analyses were carried out using 





RESULTS   
4.1 STUDY POPULATION 
Hypothyroidism complicated 2.25% of pregnancies, hyperthyroidism 
complicated 0.14% of pregnancies, other thyroid disorders complicated .27% of 
pregnancies, and unspecified thyroid disorders impacted 2.21% of pregnancies. The 
prevalence of thyroid disorders was fairly consistent amongst hospitals and across the 
years. A total of 878 (.86%) women who did not have a thyroid disorder in the first 
pregnancy developed a thyroid disorder by the time of the second pregnancy (data not 
shown). Table 4.1 provides demographic information for the study population by 
thyroid disease status.  
Compared to women without a thyroid disorder, women with hypothyroidism 
were significantly more likely to be older, have higher BMIs, be married, have private 
insurance, be White, and suffer from the following chronic diseases: diabetes, 
hypertension, heart disease, and depression. Compared to women without a thyroid 
disorder, women with hyperthyroidism were significantly more likely to be older in age, 
be multiparous, be married, and to not suffer from renal disease. Compared to women 




likely to be older in age, have higher BMIs, be married, have private insurance, be 
White, and suffer from the following chronic diseases: diabetes and depression. 
Compared to women without a thyroid disorder, women with unspecified 
thyroid disorders were significantly more likely to be older in age, have higher BMIs, 
have private insurance, be White, smoke, and suffer from the following chronic 
diseases: diabetes, hypertension, asthma, heart disease, renal disease, and depression. 
Outcomes of interest included breech presentation (n=2,259), gestational 
diabetes (n=2,096), gestational hypertension (n=3,367), hemorrhage (n=2,909), 
inductions (n=43,794), placental abruption (n= 2,205), preterm birth (n=9,773), PROM 
(n=1953), preeclampsia (n=2,813), and superimposed preeclampsia (n=220). 
4.2 HYPOTHYROIDISM  
 Unadjusted and adjusted results are presented in Tables 4.2 and 4.3, 
respectively. In the crude model, hypothyroidism was significantly associated with 
gestational diabetes [RR: 1.65, 95% CI: 1.30-2.08], preterm birth [RR: 1.27, 95% CI: 1.11-
1.45], spontaneous preterm birth [RR: 1.31, 95% CI: 1.81-3.79], and superimposed 
preeclampsia [RR: 4.00, 95% CI: 2.40-6.67] (Table 4.2). After adjusting for insurance, 
parity, race/ethnicity, age, smoking, and other chronic diseases, hypothyroidism was 
significantly associated with gestational diabetes [RR: 1.28, 95% CI: 1.00-1.63], 
gestational hypertension [RR: 1.32, 95% CI: 1.07-1.63], inductions [RR: 0.98, 95% CI: 
0.96-0.99], preterm birth [RR: 1.23, 95% CI: 1.08-1.41], and spontaneous preterm birth 




was no longer significant. The adjusted results for breech presentation, hemorrhage, 
placental abruption, PROM, and preeclampsia were not statistically significant.  
4.3 HYPERTHRYOIDISM  
In the crude model, hyperthyroidism was found to be significantly associated 
with gestational diabetes [RR: 2.93, 95% CI: 1.49-5.79], preterm birth [RR: 2.38, 95% CI: 
1.66-3.41], spontaneous preterm birth [RR: 2.62, 95% CI: 1.81-3.79], and preeclampsia 
[RR: 2.52, 95% CI 1.37-4.63]. After adjusting for insurance, parity, race/ethnicity, age, 
smoking, and other chronic diseases, hyperthyroidism was found to be significantly 
associated with gestational diabetes [RR: 2.47, 95% CI: 1.28-4.76], preterm birth [RR: 
2.31, 95% CI: 1.61-3.32], spontaneous preterm birth [RR: 2.43, 95% CI: 1.68-3.53] and 
preeclampsia [RR: 2.65, 95% CI: 1.44-4.87]. The adjusted results for breech presentation, 
gestational hypertension, hemorrhage, inductions, placental abruption, PROM, and 
superimposed preeclampsia were not statistically significant. 
4.4 OTHER THYROID DISORDERS 
 In the crude model, other thyroid disorders were found to be significantly 
associated with gestational diabetes [RR: 1.95, 95% CI: 1.15-3.32]. After adjusting for 
insurance, parity, race/ethnicity, age, smoking, and other chronic diseases, other thyroid 







4.5 UNSPECIFIED THYROID DISORDERS 
In the crude model, unspecified thyroid disorders were found to be associated 
with breech presentation [RR: 1.30, 95% CI: 1.01-1.67], gestational hypertension [RR: 
1.26, 95% CI: 1.02-1.55], inductions [RR: 1.02, 95% CI: 1.00-1.03], placental abruption 
[RR: 1.30, 95% CI: 1.01-1.64], preterm birth [RR: 1.19, 95% CI: 1.04-1.36], spontaneous 
preterm birth [RR:1.33, 95% CI: 1.16-1.53], and superimposed preeclampsia [RR: 2.20, 
95% CI: 1.04-3.91]. After adjusting for insurance, parity, race/ethnicity, age, smoking, 
and other chronic diseases, unspecified thyroid disorders were found to be significantly 
associated with gestational hypertension [RR: 1.24, 95% CI: 1.01-1.53], placental 
abruption [RR: 1.29, 95% CI: 1.01-1.64], preterm birth [RR: 1.20, 95% CI: 1.05-1.37], and 
spontaneous preterm birth [RR:1.30, 95% CI: 1.14-1.50]. Results for breech 
presentation, gestational diabetes, hemorrhage, inductions, preterm birth, PROM, 
preeclampsia, and superimposed preeclampsia were not statistically significant. 
4.6 SENSITIVITY ANALYSIS 
In the sensitivity analysis restricted to the first delivery, the results remained 
generally similar in regards to the direction of the association, although there was a loss 
of significance due to smaller sample sizes and a diminished statistical power. The 
associations between hypothyroidism and gestational diabetes [RR: 1.05; 95%CI: 0.61-
1.79], gestational hypertension [RR:1.07; 95%CI: 0.75-1.54], and preterm birth [RR:1.14, 
95%CI: 0.89-1.45] became null. The associations between hyperthyroidism and both 
preterm birth [RR:1.64; 95%CI: 0.55-4.87] and preeclampsia [RR:1.71; 95%CI: 0.83-3.52] 




gestational hypertension [RR:1.01; 95%CI: 0.99-1.02]and placental abruption [RR:1.01; 









Table 4.1 Demographic Data by Thyroid Disease Status  





P Value Hyperthyroidism 
n= 150 
P Value Other 
n= 317 




no. (%) a 
         
1 48690 
(45.26) 
668 (26.60) <.0001 48 (32.00) 0.0010 83 
(26.18) 
<.0001 1139 (41.69) <.0001 
2 47374 
(44.04) 
1413 (56.27)  78 (52.00)  186 
(58.68) 
 1278 (46.78)  
3 10243 (9.52) 375 (3.42)  21 (14.00)  41 
(12.93) 
 277 (10.14)  
≥4 1271 (1.18) 55 (2.19)  3 (2.00)  7 (2.21)  38 (1.39)  
Mean Maternal Age, 
y (SD) 
26.95 (4.72) 29.64 (4.67) <.0001 28.72 (5.05) 0.0002 29.68 
(4.37) 
<.0001 28.73 (4.67) <.0001 
Parity          
     Nulliparous 26588 
(24.72) 
316 (12.58) <.0001 23 (15.33) 0.0002 45 
(14.20) 
<.0001 513 (18.78) <.0001 
     Multiparous 80990 
(75.28) 
2195 (87.42)  127 (84.67)  272 
(85.80) 
 2219 (81.22)  
Pre-pregnancy BMI b, 
no. (%) 
         
     Underweight 8046 (7.48) 99 (3.94) <.0001 7 (4.67) 0.3942 23 
(7.26) 
0.0005 178 (6.52) <.0001 
     Normal 
     Weight 
60723 
(56.45) 
1148 (45.72)  77 (51.33)  134 
(42.27) 
 1322 (48.39)  
     Overweight 23001 
(21.38) 
618 (24.61)  25 (16.67)  74 
(23.34) 





     Obese 15808 
(14.69) 
646 (25.73)  41 (27.34)  86 
(27.13) 
 654 (23.94)  
Marital Status c, no. 
(%) 
         
     Married 106309 
(98.82) 
2477 (98.65) <.0001 148 (98.67) <.0001 314 
(99.05) 
<.0001 2693 (98.57) <.0001 
     Unmarried 1269 (1.18) 34 (1.35)  2 (1.33)  3 (0.95)  39 (1.43)  
Insurance Status          
     Private 78987 
(73.42) 
2037 (8.1.12) <.0001 116 (77.33) 0.3314 265 
(83.60) 
<.0001 2239 (81.95) <.0001 
     Public  28591 
(26.58) 
474 (18.88)  34 (22.67)  52 
(16.40) 
 493 (18.05)  
Race Ethnicity, no. 
(%) 
         
     Non-Hispanic  
     White 
92501 
(85.99) 
2364 (94.23) <.0001 135 (90.00) 0.3447 301 
(94.95) 
<.0001 2569 (94.03) <.0001 
     Hispanic 11563 
(10.75) 
113 (4.33)  5 (3.33)  11 
(3.47) 
 121 (4.33)  
     Asian/Pacific  
     Islander 
2310 (2.14) 19 (0.74)  8 (5.33)  4 (1.26)  22 (0.81)  
     Black 479 (0.45) 7 (0.28)  0 (0.00)  0 (0.00)  7 (0.26)  
     Other 725 (0.67) 8 (0.31)  2 (1.33)  1 (0.32)  13 (0.48)  
Maternal Chronic 
Disease, no. (%) 
         
    Diabetes 1597 (1.48) 110 (4.28) <.0001 4 (2.67) 0.3742 13 
(4.10) 
0.0308 95 (3.48) <.0001 





    Asthma 6719 (6.25) 188 (7.49) 0.0582 15 (10.00) 0.2173 24 
(7.57) 
0.3744 211 (7.72) 0.0179 
    Heart Disease 922 (0.86) 63 (2.51) <.0001 1 (0.67) 0.7753 5 (1.58) 0.3043 47 (1.72) 0.0050 
    Renal Disease 348 (0.32) 15 (0.60) 0.1156 0 (0.00) <.0001 0 (0.00) <.0001 23 (0.84) 0.0063 
    Gastrointestinal 
    Disease 
1269 (1.18) 34 (1.35) 0.5190 2 (1.33) 0.8694 3 (0.95) 0.6687 39 (1.43) 0.3136 
    Depression 8255 (7.67) 392 (15.61) <.0001 20 (13.33) 0.0630 48 
(15.14) 
0.0003 279 (10.21) <.0001 
Smokingd, no. (%) 3040 (2.83) 58 (2.31) 0.1690 8 (5.33) 0.3013 8 (2.52) 0.7296 49 (1.79) 0.0008 
P values were obtained from binary regression using generalized estimating equations to account for correlated data with no thyroid 
disease as comparison group. 
a All women contributed a minimum of 2 pregnancies to the data set.  
b Maternal BMI is categorized as underweight if BMI is <18.5 kg/m2, normal weight if BMI is 18.5 to 24.9 kg/m2, overweight if BMI is 
25.0 to 29.9 kg/m2, obese if BMI  
is ≥30.0 
c Marital Status frequency missing=14 












Table 4.2 Unadjusted Relative Risks of Adverse Pregnancy Outcomes among Women with Thyroid Diseases in the NICHD 









Breech Presentation 1.28 (0.99-1.65) 0.31 (0.04-2.34) 1.26 (0.57-2.35) 1.30 (1.01-1.67)* 
Gestational Diabetes a 1.65 (1.30-2.08)* 2.93 (1.49-5.79)* 1.95 (1.15-3.32)* 1.10 (0.84-1.45) 
Gestational Hypertension b 1.23 (0.99-1.52) 1.43 (0.62-3.27) 1.24 (0.70-2.20) 1.26 (1.02-1.55)* 
Hemorrhage 1.01 (0.79-1.31) 1.25 (0.52-3.01) 0.99 (0.50-1.94) 0.72 (0.54-0.95) 
Inductions  1.00 (0.98-1.01) 1.02 (0.96-1.08) 1.02 (0.98-1.06) 1.02 (1.00-1.03)* 
Placental Abruption 1.14 (0.86-1.52) 1.04 (0.34-3.17) 1.50 (0.79-2.83) 1.30 (1.01-1.64)* 
Preterm Birth 1.27 (1.11-1.45)* 2.38 (1.66-3.41)* 0.94 (0.63-1.40) 1.19 (1.04-1.36)* 
     Medically Indicated 1.12 (0.82-1.52) 1.84 (0.74-4.57) 0.17 (0.02-1.71) 0.86 (0.61-1.19) 
     Spontaneous 1.31 (1.14-1.50)* 2.62 (1.81-3.79)* 1.20 (0.81-1.77) 1.33 (1.16-1.53)* 
PROM 1.01 (0.75-1.35) 0.80 (0.21-3.03) 0.55 (0.19-1.65) 1.12 (0.85-1.47) 
Preeclampsia b 0.91 (0.68-1.21) 2.52 (1.37-4.63)* 0.75 (0.31-1.81) 0.98 (0.76-1.26) 
Superimposed Preeclampsia 4.00 (2.40-6.67)* 3.85 (0.62-24.04) 2.07 (0.38-11.17) 2.02 (1.04-3.91)* 
All numbers are RRs with 95% CIs. RRs are obtained from multivariate Poisson regression with generalized estimating equations. 
Analysis was limited to singleton pregnancies. No thyroid disease (n=108875) served as the reference group. 
*Indicates significant results. 
a Women with preexisting diabetes were excluded from the analyses of gestational diabetes. 





Table 4.3 Relative Risks of Adverse Pregnancy Outcomes among Women with Thyroid Diseases in the NICHD Consecutive 
Pregnancies Data Set 








Breech Presentation 1.24 (0.96-1.59) 0.32 (0.5-2.15) 1.12 (0.56-2.26) 1.25 (0.97-1.61) 
Gestational Diabetes a 1.28 (1.00-1.63)* 2.47 (1.28-4.76)* 1.62 (0.94-2.78) 1.00 (0.76-1.31) 
Gestational Hypertension b 1.32 (1.07-1.63)* 1.58 (0.71-3.49) 1.27 (0.72-2.26) 1.24 (1.01-1.53)* 
Hemorrhage 1.07 (0.83-1.38) 1.31 (0.55-3.11) 1.06 (0.54-2.09) 0.76 (0.58-1.01) 
Inductions  0.98 (0.96-0.99)* 1.01 (0.95-1.07) 1.00 (0.97-1.04) 1.00 (0.99-1.02) 
Placental Abruption 1.10 (0.82-1.46) 1.00 (0.33-2.99) 1.46 (0.77-2.77) 1.29 (1.01-1.64)* 
Preterm Birth 1.23 (1.08-1.41)* 2.31 (1.61-3.32)* 0.94 (0.62-1.41) 1.20 (1.05-1.37)* 
     Medically Indicated 1.03 (0.75-1.41) 1.85 (0.74-4.59) 0.17 (0.02-1.80) 0.86 (0.62-1.19 
     Spontaneous 1.25 (1.09-1.43)* 2.43 (1.68-3.53)* 1.17 (0.78-1.75) 1.30 (1.14-1.50)* 
PROM 1.09 (0.81-1.46) 0.80 (0.22-2.98) 0.59 (0.19-1.78) 1.18 (0.90-1.56) 
Preeclampsia b 1.02 (0.77-1.34) 2.65 (1.44-4.87)* 0.81 (0.34-1.91) 1.01 (0.79-1.30) 
Superimposed Preeclampsia 1.68 (0.98-2.88) 4.31 (0.90-20.69) 1.42 (0.21-9.71) 1.19 (0.59-2.38) 
All numbers are RRs with 95% CIs. RRs are obtained from multivariate Poisson regression with generalized estimating equations. All 
results are adjusted for insurance, parity, race/ethnicity, age, smoking, and other chronic diseases. Analysis was limited to singleton 
pregnancies. No thyroid disease (n=108875) served as the reference group. 
*Indicates significant results. 
a Women with preexisting diabetes were excluded from the analyses of gestational diabetes. 






Table 4.4 Relative Risks of Adverse Pregnancy Outcomes from Sensitivity Analysis Restricted to First Delivery 








Breech Presentation 1.01 (0.99-1.03) 0.98 (0.97-1.00)  1.01 (0.97-1.05) 1.01 (0.99-1.02) 
Gestational Diabetes a 1.05 (0.61-1.79) 4.50 (1.83-11.04)* 2.11 (0.68-6.56) 1.20 (0.80-1.80) 
Gestational Hypertension b 1.07 (0.75-1.54) 1.64 (0.55-4.87) 1.43 (0.61-3.32) 1.27 (0.61-3.32) 
Hemorrhage 0.89 (0.55-1.45) 1.48 (0.39-5.63) 1.33 (0.43-4.05) 0.88 (0.60-1.30) 
Inductions  0.96 (0.93-0.99) * 1.04 (0.94-1.15) 0.90 (0.84-0.97) * 1.00 (0.98-1.02) 
Placental Abruption 1.00 (0.99-1.02) 0.98 (0.97-1.00) 1.01 (0.97-1.04) 1.01 (0.99-1.02) 
Preterm Birth 1.14 (0.89-1.45) 1.71 (0.83-3.52) 0.96 (0.43-2.08) 1.18 (0.98-1.43) 
     Medically Indicated 1.01 (0.98-1.04) 1.09 (0.94-1.25) 0.98 (0.92-1.03) 1.01 (0.99-1.03) 
     Spontaneous 1.17 (0.86-1.60) 1.66 (0.62-4.41) 1.30 (0.55-1.11) 1.32 (1.05-1.66) * 
PROM 1.03 (0.61-1.74) 0.89 (0.13-6.09) 0.58 (0.08-4.05) 1.22 (0.83-1.79) 
Preeclampsia b 0.83 (0.52-1.29) 2.24 (0.88-5.70) 1.69 (0.73-3.93) 0.89 (0.63-1.26) 
Superimposed Preeclampsia 1.01 (0.99-1.02) 1.00 (0.99-1.01) 1.00 (0.99-1.01) 0.99 (0.99-1.00) 
All numbers are RRs with 95% CIs. RRs are obtained from multivariate Poisson regression with generalized estimating equations. All 
results are adjusted for insurance, parity, race/ethnicity, age, smoking, and other chronic diseases. Analysis was restricted to the first 
delivery and limited to singleton pregnancies. No thyroid disease (n=108875) served as the reference group. 
*Indicates significant results. 
a Women with preexisting diabetes were excluded from the analyses of gestational diabetes. 





DISCUSSION   
5.1 SUMMARY OF RESULTS 
In summary, the results suggest that the presence of a thyroid disorder increases 
the risk of adverse outcomes during pregnancy. This is consistent with the majority of 
previous findings-6, 9-14,19-20. Hypothyroidism, hyperthyroidism, and unspecified thyroid 
disorders were found to be associated with various adverse pregnancy outcomes. No 
significant findings were found for other thyroid disorders.  
5.2 HYPOTHYROIDISM 
 In the adjusted model, hypothyroidism was found to be associated with 
gestational diabetes, gestational hypertension, inductions, and preterm birth, which is 
consistent with the literature2,4,9,20,23,27,28. Specifically, in regards to preterm birth, it 
would appear hypothyroidism is positively associated with an increased risk of 
spontaneous preterm birth. Most of the literature has failed to specifically investigate 
the influence of thyroid disorders on induced and spontaneous preterm birth, but the 
literature does suggest that hyperthyroidism is positively associated with preterm birth 
in general 20. Männistö et al found hypothyroidism to be significantly associated with 
gestational diabetes, inductions, and preterm birth, in addition to other various adverse 




between hypothyroidism and both preterm birth and gestational diabetes23. Findings in 
the literature also indicate that hypothyroidism is associated with an increased risk of 
gestational hypertension27,28. Specifically, Chen et al found hypothyroidism to be 
associated with higher rates of gestational hypertension compared to women without a 
thyroid condition27. This supports the results from this analysis.   
 Research indicates that thyroid hormones influence various aspects of pregnancy 
and fetal growth2. Pregnancy results in a number of physiological and hormonal changes 
that may alter thyroid function2. In order to maintain normal energy and lipid 
metabolism, normal thyroid function is needed9. Additionally, weight gain or lipid 
disturbances that are often associated with hypothyroidism may increase the risk of 
adverse pregnancy outcomes9,37. Barber et al suggests that thyroid hormones play a key 
role in placentation and regulation of early pregnancy, offering a potential explanation 
for the association between hypothyroidism and gestational hypertension and preterm 
birth38. Additionally, thyroid hormones regulate cardiovascular activities and blood 
pressure, and long-term thyroid hormone disorder can result in cardiovascular 
dysfunction27. This offers more insight into the association between hypothyroidism and 
gestational hypertension. In regards to gestational diabetes, changes in weight and 
energy metabolism may offer a potential explanation for the association between 







In the adjusted model, hyperthyroidism was found to be associated with 
gestational diabetes, preterm birth, and preeclampsia. Specifically, in regards to 
preterm birth, it appears that after categorizing the outcome into spontaneous and 
induced preterm birth, it appears that spontaneous preterm birth drives this 
association. Most of the literature has failed to investigate these categories of preterm 
birth, but the literature does suggest that hyperthyroidism is positively associated with 
preterm birth 6, 9, 20, 25.  Specifically, Männistö et al found hyperthyroidism to be 
associated with almost double the odds of having a preterm delivery compared to 
individuals without a thyroid disorder9. Previous research has postulated that this 
association is directly related to the presence of thyroid antibodies20. More specifically, 
positive thyroid peroxidase antibodies have been linked to preterm delivery, however 
further research is required to identify the biological mechanism20. 
Additionally, studies within the literature support the findings on gestational 
diabetes 6, 25. Furthermore, the observed association between hyperthyroidism and 
preeclampsia is supported by the literature7, 9. Both Männistö et al and Millar et al 
found a significant association between hyperthyroidism and preeclampsia7,9. Millar et 
al further investigated this association and found the association between preeclampsia 
and hyperthyroidism to be stronger amongst women not properly treating their 
condition7. Given that previous research has indicated that the proper management of 




this suggests that the abundance of thyroid hormone during pregnancy may be the 
underlying cause of many of these adverse outcomes9,39.  
5.4 OTHER THYROID DISORDERS 
Other thyroid disorders were not found to be significantly associated with any of 
the adverse pregnancy outcomes looked at in this study. Männistö et al examined the 
relationship between other thyroid disorders and pregnancy outcomes and also 
reported null findings9. However, the Männistö study results did find a significant 
association between other thyroid disorders and PROM [RR:2.02; 95% CI: 1.23–3.30]9. 
Potential explanations for the null results will be discussed later in the chapter.   
5.5 UNSPECIFIED THYROID DISORDERS 
 Unspecified thyroid disorders were found to be associated with gestational 
hypertension, placental abruption, and preterm birth, which is consistent with previous 
research6, 9,19, 20, 23, 25,27,28. Using a similar definition of unspecified thyroid disorders, 
Männistö et al found unspecified thyroid disorders to be associated with placental 
abruption and preterm birth9. The literature also suggests that gestational hypertension 
is associated with thyroid disorders27, 28. Again, this is likely attributable to the influence 
of thyroid hormones on various aspects of pregnancy and fetal growth2. Due to the fact 
that this group only had their thyroid disease status noted in their medical records and 
did not have specific diagnoses included in their discharge summaries, it is possible that 
the individuals in this group may have had milder disease or disease that was not 




5.6 DIFFERENCES IN THE LITERATURE 
While the majority of studies within the literature found associations between 
thyroid disorders and adverse pregnancy outcomes to exist, not all studies found this to 
be true23-26. Additionally, this study failed to find significant results with various adverse 
outcomes such as breech presentation, hemorrhage, PROM, and superimposed 
preeclampsia, all of which have been previously found to have an association with 
thyroid disorders. These differences can be attributed to variation in the study 
populations, inconsistent definitions of thyroid dysfunction and outcomes of interest, 
differences in inclusion criteria, small sample sizes, and differences in patient’s baseline 
characteristics.   
5.7 STRENGTHS AND LIMITATIONS 
One particular strength of this study is the large sample size. This allowed us to 
examine less common outcomes and exposures. Additionally, a strength of this study 
lies in its ability to distinguish between spontaneous and induced preterm birth. 
Previous studies have failed to break preterm birth down into these categories and 
investigate these specific relationships20. Given the knowledge that thyroid disorders are 
associated with adverse maternal outcomes, many of which are indications for 
induction, we would expect to see an increased risk of induced preterm birth. However, 
no significant results were found for induced preterm birth. Thyroid disorders 
(hypothyroidism, hyperthyroidism, unspecified thyroid disorders) increased the risk of 




hypothyroxinemia may be associated with this increased risk of spontaneous preterm 
delivery40.   
However, despite the strengths of this study, there are some key limitations that 
need to be noted. Given the limited racial and ethnic diversity in the data, the findings 
might not be generalizable. However, the homogeneous nature of the study population 
can be seen as potentially beneficial reducing the possibility of residual confounding. 
Additionally, it is important to note that information on treatment of thyroid disorders 
during pregnancy was not available. As a result, we were unable to explore whether 
inadequate treatment was the cause of adverse pregnancy outcomes or if adverse 
pregnancy outcomes were a result of increased risk caused by the presence of a thyroid 
disease itself. Given the fact that data on treatment wasn’t collected or adjusted for in 
the model, there was a potential for residual confounding.  
5.8 FUTURE STUDIES   
Previous research has indicated that race and ethnicity may be an important 
modifying factor between the association of thyroid disorders and adverse pregnancy 
outcomes9, 31. This study contained a sample of women that was not racially and 
ethnically diverse, and therefore did not allow the influence of race on the association 
between thyroid disorders and adverse pregnancy outcomes to be studied. Throughout 
the literature, other studies have also had limited diversity and have failed to investigate 




ethnic disparities have been documented throughout multiple aspects of both health 
and health care41-45.  
As previously mentioned, this study lacked detailed information of treatment of 
individuals suffering from thyroid disorders. This is also true for other studies 
throughout the literature. It is understood that uncontrolled thyroid disease poses a 
significant threat to both the mother and fetus, however, the optimal treatment 
method is still unknown23. Some researchers hypothesize that specific treatment 
methods may pose additional risks during pregnancy23. As such, more research is 
needed to understand the influence of specific treatments of different thyroid disorders 
and how these may impact pregnancy outcomes. 
5.9 CONCLUSIONS  
The results of this study suggest that the presence of a thyroid disorder increases 
the risk of adverse outcomes during pregnancy. Specifically, this is true for 
hypothyroidism, hyperthyroidism, and unspecified thyroid diseases. This supports 
previous findings but more research involving large racially diverse cohorts with 
available data on treatment is still needed to further understand the complex 
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APPENDIX A – FULL TABLES FROM SAS OUTPUT OF MULTIVARIATE 
POISSON REGRESSION WITH GENERALIZED ESTIMATING EQUATIONS  
Table A.1 Breech Presentation 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept  -4.5849 0.1390 -4.8573 -4.3124 -32.99 <.0001 
thyroid2 Hypo 0.2128 0.1275 -0.0372 0.4627 1.67 0.0952 
thyroid2 Hyper -1.1524 0.9774 -3.0680 0.7632 -1.18 0.2384 
thyroid2 Other 0.1138 0.3573 -0.5865 0.8141 0.32 0.7501 
thyroid2 Unspec 0.2251 0.1280 -0.0259 0.4760 1.76 0.0788 
Momage  0.0415 0.0053 0.0311 0.0519 7.81 <.0001 
Race hisp 0.0151 0.0760 -0.1338 0.1640 0.20 0.8424 
Race other -0.0645 0.1240 -0.3076 0.1786 -0.52 0.6029 
smoking 2 0.3131 0.1187 0.0804 0.5459 2.64 0.0084 
parity2 1 -0.7318 0.0488 -0.8275 -0.6360 -14.98 <.0001 
Insurance 2 0.0460 0.0550 -0.0617 0.1537 0.84 0.4027 
Diabetes 2 0.4441 0.1381 0.1733 0.7148 3.21 0.0013 
ChronicHBP 2 0.4249 0.1739 0.0840 0.7658 2.44 0.0146 
Hxheartdis 2 0.4242 0.1767 0.0778 0.7706 2.40 0.0164 
Hxrenaldis 2 -0.3754 0.4151 -1.1890 0.4382 -0.90 0.3658 
Hxdepression 2 0.0320 0.0806 -0.1260 0.1900 0.40 0.6913 








Table A.2 Gestational Diabetes Mellitus  
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -7.2565 0.1351 -7.5214 -6.9916 -53.69 <.0001 
thyroid2 Hypo 0.2440 0.1239 0.0013 0.4868 1.97 0.0488 
thyroid2 Hyper 0.9152 0.3330 0.2625 1.5679 2.75 0.0060 
thyroid2 Other 0.4831 0.2770 -0.0597 1.0260 1.74 0.0811 
thyroid2 Unspec -0.0021 0.1398 -0.2761 0.2719 -0.01 0.9881 
Momage   0.1098 0.0047 0.1006 0.1190 23.51 <.0001 
race hisp 0.9572 0.0650 0.8298 1.0846 14.73 <.0001 
race other 0.9145 0.0964 0.7256 1.1034 9.49 <.0001 
smoking 2 0.3172 0.1304 0.0617 0.5727 2.43 0.0150 
parity2 1 -0.1394 0.0557 -0.2486 -0.0303 -2.50 0.0123 
Insurance 2 0.1526 0.0550 0.0448 0.2605 2.77 0.0055 
ChronicHBP 2 1.0551 0.1237 0.8126 1.2975 8.53 <.0001 
Hxheartdis 2 -0.0799 0.2389 -0.5481 0.3883 -0.33 0.7379 
Hxrenaldis 2 -0.9619 0.5662 -2.0717 0.1478 -1.70 0.0893 
Hxdepression 2 0.2983 0.0692 0.1628 0.4339 4.31 <.0001 














Table A.3 Gestational Hypertension 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -3.2414 0.1127 -3.4622 -3.0206 -28.77 <.0001 
thyroid2 Hypo 0.2781 0.1083 0.0658 0.4903 2.57 0.0102 
thyroid2 Hyper 0.4532 0.4054 -0.3414 1.2479 1.12 0.2636 
thyroid2 Other 0.2402 0.2930 -0.3342 0.8145 0.82 0.4124 
thyroid2 Unspec 0.2179 0.1053 0.0115 0.4243 2.07 0.0385 
Momage   0.0159 0.0044 0.0074 0.0244 3.65 0.0003 
race hisp -0.4039 0.0743 -0.5496 -0.2582 -5.43 <.0001 
race other -0.3671 0.1249 -0.6118 -0.1224 -2.94 0.0033 
smoking 2 -0.3494 0.1301 -0.6044 -0.0943 -2.68 0.0073 
parity2 1 -1.0436 0.0376 -1.1173 -0.9699 -27.74 <.0001 
Insurance 2 -0.0618 0.0462 -0.1524 0.0289 -1.34 0.1817 
Diabetes 2 0.6279 0.1138 0.4048 0.8510 5.52 <.0001 
Hxheartdis 2 0.0629 0.1818 -0.2934 0.4192 0.35 0.7294 
Hxrenaldis 2 0.6822 0.2000 0.2902 1.0742 3.41 0.0006 
Hxdepression 2 0.2068 0.0642 0.0809 0.3327 3.22 0.0013 














Table A.4 Hemorrhage 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -3.5219 0.1152 -3.7476 -3.2961 -30.58 <.0001 
thyroid2 Hypo 0.0662 0.1282 -0.1851 0.3176 0.52 0.6056 
thyroid2 Hyper 0.2719 0.4429 -0.5963 1.1401 0.61 0.5393 
thyroid2 Other 0.0584 0.3464 -0.6205 0.7372 0.17 0.8662 
thyroid2 Unspec -0.2699 0.1424 -0.5490 0.0093 -1.89 0.0581 
Momage   -0.0013 0.0045 -0.0101 0.0074 -0.29 0.7688 
race hisp 0.5379 0.0564 0.4273 0.6485 9.53 <.0001 
race other 0.5784 0.0861 0.4098 0.7471 6.72 <.0001 
smoking 2 -0.0051 0.1156 -0.2316 0.2215 -0.04 0.9649 
parity2 1 -0.3846 0.0434 -0.4697 -0.2996 -8.86 <.0001 
Insurance 2 0.0828 0.0463 -0.0079 0.1735 1.79 0.0735 
Diabetes 2 0.3175 0.1298 0.0632 0.5718 2.45 0.0144 
ChronicHBP 2 0.6512 0.1405 0.3759 0.9265 4.64 <.0001 
Hxheartdis 2 0.1857 0.1806 -0.1683 0.5397 1.03 0.3039 
Hxrenaldis 2 0.3630 0.2808 -0.1874 0.9134 1.29 0.1961 
Hxdepression 2 0.3167 0.0639 0.1914 0.4421 4.95 <.0001 







Table A.5 Inductions 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   0.2878 0.0070 0.2740 0.3015 41.04 <.0001 
thyroid2 Hypo -0.0237 0.0076 -0.0386 -0.0087 -3.11 0.0019 
thyroid2 Hyper 0.0062 0.0302 -0.0530 0.0654 0.21 0.8375 
thyroid2 Other 0.0021 0.0191 -0.0353 0.0396 0.11 0.9107 
thyroid2 Unspec 0.0025 0.0072 -0.0115 0.0166 0.35 0.7243 
Momage   0.0020 0.0003 0.0015 0.0025 7.39 <.0001 
race hisp -0.1054 0.0040 -0.1131 -0.0976 -26.55 <.0001 
race other -0.0825 0.0065 -0.0951 -0.0699 -12.79 <.0001 
smoking 2 -0.0401 0.0069 -0.0536 -0.0267 -5.85 <.0001 
parity2 1 0.0048 0.0026 -0.0003 0.0099 1.85 0.0649 
Insurance 2 -0.0228 0.0028 -0.0283 -0.0174 -8.23 <.0001 
Diabetes 2 0.0102 0.0091 -0.0077 0.0281 1.12 0.2631 
ChronicHBP 2 0.0927 0.0105 0.0722 0.1131 8.87 <.0001 
Hxheartdis 2 -0.0168 0.0116 -0.0395 0.0060 -1.44 0.1487 
Hxrenaldis 2 0.0176 0.0178 -0.0173 0.0525 0.99 0.3218 
Hxdepression 2 0.0014 0.0040 -0.0064 0.0092 0.36 0.7192 






Table A.6 Placental Abruption 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -4.3307 0.1405 -4.7061 -4.1552 -31.53 <.0001 
thyroid2 Hypo 0.0920 0.1458 -0.1938 0.3779 0.63 0.5280 
thyroid2 Hyper 0.0007 0.5590 -1.0950 1.0963 0.00 0.9990 
thyroid2 Other 0.3812 0.3264 -0.2585 1.0210 1.17 0.2429 
thyroid2 Unspec 0.2514 0.1227 0.0109 0.4918 2.05 0.0404 
Momage   0.0084 0.0053 -0.0020 0.0188 1.58 0.1147 
race hisp 0.0588 0.0721 -0.0825 0.2000 0.82 0.4149 
race other 0.0240 0.1184 -0.2081 0.2561 0.20 0.8394 
smoking 2 0.6473 0.0946 0.4620 0.8326 6.85 <.0001 
parity2 1 0.1454 0.0565 0.0348 0.2561 2.58 0.0100 
Insurance 2 0.2600 0.0526 0.1568 0.3631 4.94 <.0001 
Diabetes 2 0.2307 0.1487 -0.0607 0.5221 1.55 0.1208 
ChronicHBP 2 0.0393 0.2000 -0.3526 0.4313 0.20 0.8441 
Hxheartdis 2 0.3375 0.1960 -0.0467 0.7217 1.72 0.0851 
Hxrenaldis 2 0.4513 0.2859 -0.1091 1.0118 1.58 0.1145 
Hxdepression 2 0.1489 0.0725 0.0069 0.2909 2.05 0.0399 







Table A7 Preterm Birth 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -2.3647 0.0762 -2.5142 -2.2153 -31.01 <.0001 
thyroid2 Hypo 0.2093 0.0674 0.0771 0.3415 3.10 0.0019 
thyroid2 Hyper 0.8366 0.1852 0.4735 1.1996 4.52 <.0001 
thyroid2 Other -0.0665 0.2092 -0.4765 0.3435 -0.32 0.7505 
thyroid2 Unspec 0.1831 0.0676 0.0505 0.3157 2.71 0.0068 
Momage   -0.0127 0.0030 -0.0185 -0.0069 -4.30 <.0001 
race hisp 0.0263 0.0392 -0.0505 0.1031 0.67 0.5020 
race other 0.2341 0.0566 0.1231 0.3451 4.13 <.0001 
smoking 2 0.6919 0.0467 0.6004 0.7834 14.82 <.0001 
parity2 1 -0.0438 0.0253 -0.0934 0.0058 -1.73 0.0832 
Insurance 2 0.1548 0.0271 0.1016 0.2080 5.70 <.0001 
Diabetes 2 0.7239 0.0613 0.6039 0.8440 11.82 <.0001 
ChronicHBP 2 0.6116 0.0806 0.4536 0.7695 7.59 <.0001 
Hxheartdis 2 0.3785 0.0923 0.1977 0.5594 4.10 <.0001 
Hxrenaldis 2 0.5283 0.1261 0.2811 0.7755 4.19 <.0001 
Hxdepression 2 0.2544 0.0351 0.1857 0.3232 7.25 <.0001 







Table A.8 PROM 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -3.7294 0.1488 -4.0210 -3.4378 -25.06 <.0001 
thyroid2 Hypo 0.0863 0.1512 -0.2102 0.3827 0.57 0.5684 
thyroid2 Hyper -0.2234 0.6698 -1.5363 1.0894 -0.33 0.7387 
thyroid2 Other -0.5323 0.5648 -1.6394 0.5747 -0.94 0.3460 
thyroid2 Unspec 0.1682 0.1412 -0.1085 0.4449 1.19 0.2336 
Momage   -0.0016 0.0059 -0.0131 0.0099 -0.27 0.7878 
race hisp 0.0765 0.0774 -0.0751 0.2282 0.99 0.3225 
race other 0.2026 0.1173 -0.0273 0.4325 1.73 0.0841 
smoking 2 0.7847 0.0993 0.5901 0.9793 7.90 <.0001 
parity2 1 -0.6227 0.0536 -0.7277 -0.5176 -11.62 <.0001 
Insurance 2 0.1571 0.0571 0.0453 0.2689 2.75 0.0059 
Diabetes 2 0.5150 0.1537 0.2138 0.8163 3.35 0.0008 
ChronicHBP 2 -0.0275 0.2214 -0.4613 0.4064 -0.12 0.9013 
Hxheartdis 2 0.3179 0.2047 -0.0833 0.7191 1.55 0.1204 
Hxrenaldis 2 -0.4260 0.4561 -1.3199 0.4679 -0.93 0.3502 
Hxdepression 2 0.2325 0.0788 0.0780 0.3870 2.95 0.0032 







Table A.9 Preeclampsia 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -3.4589 0.1249 -3.7037 -3.2141 -27.69 <.0001 
thyroid2 Hypo 0.0156 0.1417 -0.2622 0.2934 0.11 0.9125 
thyroid2 Hyper 0.9783 0.3100 0.3708 1.5859 3.16 0.0016 
thyroid2 Other -0.2155 0.4406 -1.0790 0.6480 -0.49 0.6247 
thyroid2 Unspec 0.0141 0.1276 -0.2361 0.2642 0.11 0.9123 
Momage   0.0143 0.0049 0.0048 0.0238 2.95 0.0032 
race hisp -0.0118 0.0698 -0.1487 0.1250 -0.17 0.8652 
race other 0.2733 0.1004 0.0765 0.4701 2.72 0.0065 
smoking 2 0.0907 0.1141 -0.1329 0.3142 0.79 0.4267 
parity2 1 -1.1228 0.0418 -1.2047 -1.0410 -26.89 <.0001 
Insurance 2 0.1195 0.0479 0.0257 0.2134 2.50 0.0125 
Diabetes 2 0.9535 0.1068 0.7442 1.1628 8.93 <.0001 
Hxheartdis 2 0.4014 0.1770 0.0545 0.7482 2.27 0.0233 
Hxrenaldis 2 0.9626 0.2029 0.5650 1.3603 4.74 <.0001 
Hxdepression 2 0.3424 0.0687 0.2079 0.4770 4.99 <.0001 






Table A.10 Superimposed Preeclampsia 
Analysis Of GEE Parameter Estimates 
Empirical Standard Error Estimates 




Z Pr > |Z| 
Intercept   -8.8285 0.3908 -9.5944 -8.0627 -22.59 <.0001 
thyroid2 Hypo 0.5182 0.2759 -0.0226 1.0590 1.88 0.0604 
thyroid2 Hyper 1.4585 0.8010 -0.1114 3.0285 1.82 0.0686 
thyroid2 Other 0.3472 0.9827 -1.5788 2.2732 0.35 0.7239 
thyroid2 Unspec 0.1737 0.3545 -0.5212 0.8686 0.49 0.6242 
Momage   0.0802 0.0149 0.0510 0.1094 5.39 <.0001 
race hisp 0.6890 0.2274 0.2432 1.1347 3.03 0.0025 
race other 0.0535 0.3619 -0.6557 0.7628 0.15 0.8824 
smoking 2 0.5684 0.3269 -0.0723 1.2091 1.74 0.0821 
parity2 1 -0.5976 0.1848 -0.9598 -0.2354 -3.23 0.0012 
Insurance 2 0.1598 0.1792 -0.1914 0.5109 0.89 0.3726 
Diabetes 2 0.7310 0.2429 0.2549 1.2072 3.01 0.0026 
Hxheartdis 2 -0.6098 0.6026 -1.7909 0.5713 -1.01 0.3116 
Hxrenaldis 2 1.7754 0.3632 1.0635 2.4873 4.89 <.0001 
ChronicHBP 2 3.5258 0.2155 3.1034 3.9482 16.36 <.0001 
Hxdepression 2 0.5070 0.1951 0.1247 0.8893 2.60 0.0093 
Hxasthma 2 0.6514 0.2056 0.2485 1.0543 3.17 0.0015 
 
 
 
 
 
 
 
 
